Walleye Capital
CAI

Walleye Capital’s Caris Life Sciences CAI Stock Holding History

Walleye Capital’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.56M Buy
+424,407
New +$7.6M 0.03% 601
2026
Q1 		– Sell
-162,915
Closed -$4.4M – 5130
2025
Q4 		$4.4M Sell
162,915
-157,754
-49% -$4.44M 0.01% 1242
2025
Q3 		$9.7M Buy
320,669
+282,741
+745% +$9.02M 0.04% 561
2025
Q2 		$1.01M Buy
+37,928
New +$1.02M ﹤0.01% 2047

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Walleye Capital's CAI Position: Q2 2026 in Review

Walleye Capital opened a new position in Caris Life Sciences (CAI) in Q2 2026: 424,407 shares worth $7.56M. The stake represents 0.03% of the portfolio and ranks #601 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CAI as recently as Q4 2025.

Walleye Capital first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $9.7M in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Walleye Capital held 424,407 shares of Caris Life Sciences worth $7.56M as of Q2 2026.
  • Caris Life Sciences was a new Walleye Capital position in Q2 2026.
  • Caris Life Sciences made up 0.03% of Walleye Capital's portfolio in Q2 2026, its #601 holding.
  • Walleye Capital first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • Walleye Capital's Caris Life Sciences position peaked at $9.7M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.